{"id":"neostigmine-glycopyrronium","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Muscle weakness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central nervous system. Glycopyrronium is an anticholinergic agent added to this combination to prevent excessive parasympathomimetic effects (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. This combination is used to enhance neuromuscular transmission while maintaining tolerability.","oneSentence":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrronium blocks muscarinic receptors to counteract cholinergic side effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:01.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myasthenia gravis"},{"name":"Reversal of neuromuscular blockade"}]},"trialDetails":[{"nctId":"NCT03229486","phase":"PHASE4","title":"Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium Anesthesia","status":"COMPLETED","sponsor":"Pusan National University Yangsan Hospital","startDate":"2017-03-01","conditions":"Emergence Delirium","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neostigmine"],"phase":"marketed","status":"active","brandName":"Neostigmine+Glycopyrronium","genericName":"Neostigmine+Glycopyrronium","companyName":"Pusan National University Yangsan Hospital","companyId":"pusan-national-university-yangsan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrronium blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}